An exploratory 8-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, ...

Results from the phase 3 PAPILLON study show that first-line amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) was associated with numerically longer overall survival compared with chemotherapy ...